4DMedical Limited

4DMedical is a global medical technology company headquartered in Melbourne, Victoria, Australia, with additional offices in Los Angeles, California, United States. The company's core business revolves around transforming respiratory imaging to improve outcomes for individuals with lung disease. Its mission is to enhance global health by providing unique, non-invasive imaging technologies that offer unprecedented insights into pulmonary functioning, crucial for the analysis and management of various respiratory conditions.

4DMedical offers a suite of innovative software and hardware products, including its flagship XV Technology®. Key offerings include the FDA-cleared XV LVAS (X-ray Velocimetry Lung Ventilation Analysis Software), CT LVAS (Computed Tomography Lung Ventilation Analysis Software), and CT:VQ™. The company also provides the XV Scanner, a dedicated lung scanner, and various other software solutions such as CAC, IQ-UIP, LDAf, LDAi, LTA, and PHA Analysis. These products are commercialized through a Software as a Service (SaaS) model, integrating with existing imaging equipment to provide quantitative lung ventilation data.

In recent news, 4DMedical received CE Mark certification for its CT:VQ™ technology in March 2026, enabling its commercial launch across the European Union. Philips has also entered into a distribution agreement to make 4DMedical's CT:VQ™ available across healthcare systems in the U.S. and Canada. The company was added to the All Ordinaries index in March 2026 and secured a $10 million strategic investment from Pro Medicus, alongside a $150 million institutional placement. Dr. Andreas Fouras serves as the Founder, Managing Director, and CEO, with Julian Sutton appointed as CFO and Executive Director in January 2026.